# Gadolinium Contrast-enhanced Abbreviated MRI (AMRI) vs. Standard Ultrasound for Hepatocellular Carcinoma (HCC) Surveillance in Patients With Cirrhosis

> **NCT04288323** · PHASE4 · COMPLETED · sponsor: **University of California, San Diego** · enrollment: 79 (actual)

## Conditions studied

- Liver Cancer
- Liver Cirrhoses
- Liver Carcinoma

## Interventions

- **DRUG:** Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid

## Key facts

- **NCT ID:** NCT04288323
- **Lead sponsor:** University of California, San Diego
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-27
- **Primary completion:** 2025-12-16
- **Final completion:** 2025-12-16
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2026-02-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04288323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04288323, "Gadolinium Contrast-enhanced Abbreviated MRI (AMRI) vs. Standard Ultrasound for Hepatocellular Carcinoma (HCC) Surveillance in Patients With Cirrhosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04288323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*